Paris (France), 16th March 2021 – PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, today announce that they have been granted approval from the French National Agency for Medicines and Health Products (ANSM) to proceed with the first-in-human clinical trial of PEP-Therapy’s lead drug candidate, PEP-010.

SATT Lutech is pleased with the authorization granted to Pep Therapy by ANSM to start a clinical phase in humans for the development of its drug candidate PEP010.
This anti-tumor peptide, from the CIMI Paris laboratory, has been the subject of a technology transfer operated by SATT Lutech.